Sunshine Lake Pharma Co. Ltd. has disclosed poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.
including a ‘next-generation’ PARP inhibitor and an antibody-drug conjugate. The deal includes an upfront fee of €160 million ($169 million) and could swell to €1.4 billion if development ...
Schomburg said Eisbach views EIS-12656 as an alternative to poly-ADP-ribose polymerase inhibitors (PARP) inhibitors in therapy ... helicase-DNA-binding protein 1-like), a chromatin remodeller ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback